Lipella Pharmaceuticals Company Description

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications.

It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer.

Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

Lipella Pharmaceuticals Inc.

Country	United States
Founded	2005
Industry	Biotechnology
Sector	Healthcare
Employees	7
CEO	Jonathan Kaufman

Contact Details

Address: 7800 Susquehanna St. Pittsburgh, Delaware 15208 United States
Phone	412 894 1853
Website	lipella.com

Stock Details

Ticker Symbol	LIPO
Exchange	OTCMKTS
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US53630L2097
SIC Code	2836

Key Executives

Name	Position
Dr. Jonathan Kaufman M.B.A., Ph.D.	Co-Founder, Chairman, Chief Executive Officer, President, Secretary and Treasurer
Dr. Michael B. Chancellor M.D.	Co-Founder, Chief Medical Officer and Director
Douglas Johnston CPA	Chief Financial Officer
Michele Gruber	Director of Operations
Janet Okonski	Director of Clinical Operations
Katie Johnston	Controller